Investment Analysts’ Updated EPS Estimates for January, 17th (ARNA, AVXS, COUP, EL, ESPR, EXAS, INSM, ONCE, RARE, USB)

Investment Analysts’ updated eps estimates for Wednesday, January 17th:

Credit Suisse Group AG started coverage on shares of Arena Pharmaceuticals (NASDAQ:ARNA). They issued an outperform rating and a $44.00 price target on the stock.

Credit Suisse Group AG assumed coverage on shares of AveXis (NASDAQ:AVXS). The firm issued an outperform rating and a $134.00 target price on the stock.

Coupa Software (NASDAQ:COUP) was given a $41.00 price target by analysts at Northland Securities. The firm currently has a buy rating on the stock.

Estee Lauder Companies (NYSE:EL) was given a $148.00 target price by analysts at Jefferies Group LLC. The firm currently has a buy rating on the stock.

Credit Suisse Group AG assumed coverage on shares of Esperion Therapeutics (NASDAQ:ESPR). The firm issued an outperform rating and a $103.00 target price on the stock.

EXACT Sciences (NASDAQ:EXAS) was given a $65.00 target price by analysts at Benchmark Co.. The firm currently has a buy rating on the stock.

Credit Suisse Group AG assumed coverage on shares of Insmed (NASDAQ:INSM). They issued a neutral rating and a $31.00 price target on the stock.

Credit Suisse Group AG assumed coverage on shares of Spark Therapeutics (NASDAQ:ONCE). The firm issued an outperform rating and a $61.00 price target on the stock.

Credit Suisse Group AG assumed coverage on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE). They issued an outperform rating and a $67.00 target price on the stock.

U.S. Bancorp (NYSE:USB) had its hold rating reaffirmed by analysts at Oppenheimer Holdings Inc..

YY (NASDAQ:YY) was upgraded by analysts at Nomura from a neutral rating to a buy rating.

Receive News & Ratings for Arena Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arena Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit